Your session is about to expire
← Back to Search
NUV-868 + Olaparib/Enzalutamide for Cancer
Study Summary
This trial is testing a new drug, NUV-868, for safety and efficacy in patients with advanced solid tumors. The drug will be taken orally, either as a monotherapy or in combination with other drugs olaparib or enzalutamide, in 28-day cycles. The trial will continue until the disease progresses, there are unacceptable side effects, the patient withdraws consent, or the trial is terminated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My advanced cancer has worsened despite treatment, or there's no effective treatment for it.My cancer is one of the specified types: ovarian, pancreatic, prostate, or breast.My cancer can be measured or seen on tests.I haven't taken experimental drugs recently.You are expected to live for more than 3 months.I haven't had cancer treatment like chemo, hormone therapy, or radiation in the last 14 days.I have recovered from side effects of previous cancer treatments.I do not have any active brain or spinal cord diseases.My organs and bone marrow are working well.I have recovered from side effects of previous cancer treatments.I do not have any active brain or spinal cord diseases.My BRCA/HRR status does not affect my eligibility for this study.My bone marrow and organs are functioning well.My cancer can be measured or is known to be present.I can perform all self-care but may not be able to work.I am currently pregnant or breastfeeding.I need medication that strongly affects certain liver enzymes.
- Group 1: Phase 2: Enzalutamide Monotherapy
- Group 2: Phase 1 Monotherapy
- Group 3: Phase 1b Combination: NUV-868 + Olaparib
- Group 4: Phase 1b Combination: NUV-868 + Enzalutamide
- Group 5: Phase 2 Combination: NUV-868 + Olaparib
- Group 6: Phase 2 Combination: NUV-868 + Enzalutamide
- Group 7: Phase 2: NUV-868 Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people still able to sign up for this experiment?
"That is accurate. The information available on clinicaltrials.gov demonstrates that this study, which was initially posted on 3/29/2022, is still recruiting participants. 246 individuals are needed for the trial taking place at 7 different locations."
Are there any other locations where this experiment is taking place?
"Currently, there are 7 sites enrolling patients for this trial. The locations of these centres include Baltimore, Detroit, Huntersville and other cities. To reduce the amount of travel required, make sure to select the centre nearest you when enrolling."
How many people are eligible to participate in this research project?
"In order to run the study, 246 people who meet the clinical trial's requirements must be recruited. The sponsor, Nuvation Bio Inc., will manage and operate the trial from different locations which include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland as well as Karmanos Cancer Institute in Detroit, Michigan."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger